🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to health experts.

A Global Health Concern

Cases of gonorrhoea are increasing globally, with figures suggesting over 82 million infections annually. Especially elevated rates are observed in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

One new antibiotic, alternatively called a brand name, was approved by the US FDA in December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists hope that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GSK, was also approved in close succession. This treatment, which is employed against urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Research Study Outcomes and Worldwide Availability

Based on findings detailed in a major medical journal, the new drug successfully treated the vast majority of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which combines an injection and a pill. The research involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to make available and distribute the drug in many developing nations.

Doctors on the front lines have shared hope. Having a single-dose, oral treatment such as this is described as a "revolutionary step" for gonorrhoea control. This is considered crucial to reduce the burden of the illness for people and to prevent the spread of untreatable gonorrhoea around the world.